{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:51:24Z","timestamp":1791215484605,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82502740"],"award-info":[{"award-number":["82502740"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ijid.2026.108863","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T15:33:33Z","timestamp":1781537613000},"page":"108863","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["In vitro activity of cefiderocol and sulbactam-durlobactam against clinical-isolated carbapenem-resistant Acinetobacter baumannii from China"],"prefix":"10.1016","volume":"170","author":[{"given":"Yixin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohan","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2015-6224","authenticated-orcid":false,"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2026.108863_bib0001","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1093\/ofid\/ofy293","article-title":"Antimicrobial susceptibility of Acinetobacter calcoaceticus-Acinetobacter baumannii complex and Stenotrophomonas maltophilia clinical isolates: results from the SENTRY Antimicrobial Surveillance Program (1997-2016)","volume":"6","author":"Gales","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijid.2026.108863_bib0002","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ijid.2022.12.010","article-title":"Geographic patterns of Acinetobacter baumannii and carbapenem resistance in the Asia-Pacific Region: results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2012-2019","volume":"127","author":"Lee","year":"2023","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijid.2026.108863_bib0003","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0140-6736(24)02081-6","article-title":"Multidrug-resistant gram-negative bacterial infections","volume":"405","author":"Macesic","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2026.108863_bib0004","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00234-23","article-title":"Contribution of iron-transport systems and \u03b2-lactamases to cefiderocol resistance in clinical isolates of Acinetobacter baumannii endemic to New York City","volume":"67","author":"Asrat","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2026.108863_bib0005","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1473-3099(18)30099-9","article-title":"Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant gram-negative bacteria: an open-label, randomised controlled trial","volume":"18","author":"Paul","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2026.108863_bib0006","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s10096-020-04121-1","article-title":"Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review","volume":"41","author":"Yaghoubi","year":"2022","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijid.2026.108863_bib0007","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01110-18","article-title":"New treatment options against carbapenem-resistant Acinetobacter baumannii infections","volume":"63","author":"Isler","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2026.108863_bib0008","article-title":"Treatment of infections caused by carbapenem-resistant Acinetobacter baumannii","volume":"14","author":"Zhang","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.ijid.2026.108863_bib0009","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijid.2026.108863_bib0010","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00079-17","article-title":"Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae","volume":"31","author":"Rodr\u00edguez-Ba\u00f1o","year":"2018","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijid.2026.108863_bib0011","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40265-019-1055-2","article-title":"Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant gram-negative Bacilli","volume":"79","author":"Zhanel","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ijid.2026.108863_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.101034","article-title":"Cefiderocol: clinical application and emergence of resistance","volume":"72","author":"Wang","year":"2024","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.ijid.2026.108863_bib0013","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02712-21","article-title":"In vitro activity of cefiderocol against U.S. and European gram-negative clinical isolates collected in 2020 as part of the SENTRY Antimicrobial Surveillance Program","volume":"10","author":"Shortridge","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.ijid.2026.108863_bib0014","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s00134-024-07341-7","article-title":"Invasive Fungal diseases in adult patients in Intensive Care Unit (FUNDICU): 2024 consensus definitions from ESGCIP, EFISG, ESICM, ECMM, MSGERC, ISAC, and ISHAM","volume":"50","author":"Bassetti","year":"2024","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijid.2026.108863_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106882","article-title":"Prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: review of the evidence","volume":"62","author":"Kollef","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijid.2026.108863_bib0016","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2026.108863_bib0017","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2026.108863_bib0018","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/14787210.2024.2440018","article-title":"Unraveling sulbactam-durlobactam: insights into its role in combating infections caused by Acinetobacter baumannii","volume":"23","author":"Fu","year":"2025","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijid.2026.108863_bib0019","doi-asserted-by":"crossref","first-page":"124","DOI":"10.12688\/wellcomeopenres.14826.1","article-title":"Open-access bacterial population genomics: BIGSdb software, the PubMLST.Org website and their applications","volume":"3","author":"Jolley","year":"2018","journal-title":"Wellcome Open Res"},{"key":"10.1016\/j.ijid.2026.108863_bib0020","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00877-21","article-title":"Contribution of PER-type and NDM-type \u03b2-lactamases to cefiderocol resistance in Acinetobacter baumannii","volume":"65","author":"Poirel","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2026.108863_bib0021","doi-asserted-by":"crossref","first-page":"S565","DOI":"10.1093\/cid\/ciz830","article-title":"Treatment options for carbapenem-resistant gram-negative bacterial infections","volume":"69","author":"Doi","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2026.108863_bib0022","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01990-21","article-title":"In vitro susceptibility of gram-negative pathogens to cefiderocol in five consecutive annual multinational SIDERO-WT surveillance studies, 2014 to 2019","volume":"66","author":"Karlowsky","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2026.108863_bib0023","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00828-22","article-title":"Structural basis of PER-1-mediated cefiderocol resistance and synergistic inhibition of PER-1 by cefiderocol in combination with Avibactam or Durlobactam in Acinetobacter baumannii","volume":"66","author":"Liu","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2026.108863_bib0024","doi-asserted-by":"crossref","first-page":"261","DOI":"10.21037\/atm-22-889","article-title":"Susceptibility of cefiderocol and other antibiotics against carbapenem-resistant, gram-negative bacteria","volume":"10","author":"Wang","year":"2022","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.ijid.2026.108863_bib0025","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1089\/mdr.2021.0180","article-title":"Mechanisms of reduced susceptibility to cefiderocol among isolates from the CREDIBLE-CR and APEKS-NP clinical trials","volume":"28","author":"Nordmann","year":"2022","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.ijid.2026.108863_bib0026","article-title":"Cefiderocol: systematic review of mechanisms of resistance, heteroresistance and in vivo emergence of resistance","volume":"11","author":"Karakonstantis","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.ijid.2026.108863_bib0027","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1128\/AAC.01795-10","article-title":"PER-7, an extended-spectrum beta-lactamase with increased activity toward broad-spectrum cephalosporins in Acinetobacter baumannii","volume":"55","author":"Bonnin","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2026.108863_bib0028","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01221-20","article-title":"Cefiderocol resistance in Acinetobacter baumannii: roles of \u03b2-lactamases, siderophore receptors, and penicillin binding protein 3","volume":"64","author":"Malik","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2026.108863_bib0029","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01454-17","article-title":"In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against gram-negative bacteria","volume":"62","author":"Ito","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2026.108863_bib0030","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00290-24","article-title":"Treatment-emergent cefiderocol resistance in carbapenem-resistant Acinetobacter baumannii is associated with insertion sequence ISAba36 in the siderophore receptor pirA","volume":"68","author":"Huang","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2026.108863_bib0031","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/jac\/dkae018","article-title":"In vivo development of cefiderocol resistance in carbapenem-resistant Acinetobacter baumannii associated with the downregulation of a TonB-dependent siderophore receptor, PiuA","volume":"79","author":"Findlay","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2026.108863_bib0032","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1093\/jac\/dkaa119","article-title":"In vitro activity of sulbactam\/durlobactam against clinical isolates of Acinetobacter baumannii collected in China","volume":"75","author":"Yang","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2026.108863_bib0033","article-title":"Acinetobacter baumannii resistance to Sulbactam\/durlobactam: a systematic review","volume":"11","author":"Principe","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.ijid.2026.108863_bib0034","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/cid\/ciad556","article-title":"Clinical outcomes and bacterial characteristics of carbapenem-resistant Acinetobacter baumannii among patients from different global regions","volume":"78","author":"Wang","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2026.108863_bib0035","article-title":"Activity of sulbactam-durlobactam and comparators against a national collection of carbapenem-resistant Acinetobacter baumannii isolates from Greece","volume":"11","author":"Petropoulou","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.ijid.2026.108863_bib0036","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jgar.2022.05.011","article-title":"In vitro activity of sulbactam-durlobactam against carbapenem-resistant Acinetobacter baumannii and mechanisms of resistance","volume":"30","author":"Findlay","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.ijid.2026.108863_bib0037","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00665-23","article-title":"Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates of Acinetobacter baumannii","volume":"67","author":"Moussa","year":"2023","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226004984?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226004984?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:56:11Z","timestamp":1791212171000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971226004984"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":37,"alternative-id":["S1201971226004984"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108863","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of cefiderocol and sulbactam-durlobactam against clinical-isolated carbapenem-resistant Acinetobacter baumannii from China","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108863","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"108863"}}